Major Depressive Disorder Clinical Trial
Official title:
Exploring Biomarkers for Depression
NCT number | NCT01424111 |
Other study ID # | AMD-CS-0007 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 2011 |
Est. completion date | October 14, 2017 |
Verified date | April 2018 |
Source | Wyss Institute at Harvard University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this research is to explore objective biomarkers in voice, physiological, motor, and brain imaging signals that may one day be used to complement clinical evaluation and treatment of depression.
Status | Completed |
Enrollment | 51 |
Est. completion date | October 14, 2017 |
Est. primary completion date | October 14, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Treatment Group Inclusion Criteria: 1. Men or women age 18-65; 2. Written informed consent; 3. Meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for current major depressive episode (MDE); 4. Hamilton Rating Scale for Depression (HAM-D-17) baseline score = 16. Treatment Group Exclusion Criteria: 1. Subjects whose first language is not English; 2. In women, pregnancy, plans to conceive, or unwillingness to comply with birth control requirements; 3. Subjects with a baseline Clinical Global Impressions-Severity score of 6 or 7; 4. Subjects with suicidal ideation where outpatient treatment is determined unsafe by the clinician. These subjects will be immediately referred to appropriate clinical treatment; 5. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease; 6. History of seizure disorder; 7. History or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, including alcohol, active within the last 12 months; 8. Subjects with mood congruent or mood incongruent psychotic features; 9. Clinical or laboratory evidence of hypothyroidism; 10. Positive urine drug screen at evaluation visit; 11. Electro Convulsive Therapy (ECT) during the last year; 12. Subjects who have failed to respond during the course of their current major depressive episode to a trial of escitalopram (at least 40mg/day for six weeks or more) 13. History of intolerance to citalopram or escitalopram; 14. Subjects requiring excluded medications including antidepressants, anorexics, antiarrhythmics, and other psychotropic agents (including lithium, benzodiazepine sedatives, other sedatives, and anti-seizure medications), beta-blockers (such as metoprolol or propranolol) ketoconazole, itraconazole, fluconazole, erythromycin, omeprazole, cimetidine, dehydroepiandrosterone (DHEA), entacapone, hydroxytryptophan (5-HTP), ginkgo, St. John's Wort (hypercium), naratriptan, rizatriptan, sibutramine, zolmitriptan and warfarin (Coumadin). 15. Subjects who have failed two or more adequate antidepressant trials during the current Major Depressive Episode (MDE) If a subject is deemed eligible from the above criteria, there is additional exclusion criteria required to participate in Martinos Center study visits, listed below. Subjects meeting any of the below criteria will not be allowed to participate in visits to the Martinos Center. 16. Subjects of weight above 300 lbs. (limit for 1.5T Siemens Sonata whole body scanner used in MRI data acquisition); 17. History of significant head trauma (unconsciousness for 10 minutes or longer); 18. Surgical aneurysm clips; 19. Cardiac pacemaker; 20. Prosthetic heart valve; 21. Use of a neurostimulator; 22. Implanted pumps; 23. Cochlear implants; 24. Metal rods, plates, or screws in the body, or metal foil medical skin patches that cannot be removed; 25. IUD; 26. Previous head surgery; 27. Hearing aid; 28. Non-removable dentures, root canals, dental implants, bridges, and wires in the mouth; 29. Currently breastfeeding; 30. Meniere's Disease; 31. Metal (shiny) tattoos or metal body jewelry that cannot be removed; 32. Claustrophobia; 33. Abnormal hearing; 34. Glasses with vision correction greater than +/- 6 diopters. Healthy/Control Group Inclusion Criteria: 1. Men or Women, ages 18-65; 2. Written informed consent; 3. QIDS-SR score of < 8 at Screening Visit; 4. Agrees to, and is eligible for, all biomarkers procedures (M/EEG, MRI, physiological recordings); Healthy/Control Group Exclusion Criteria: 1. Subjects whose first language is not English; 2. Current or lifetime history for major depressive disorder, psychotic depression bipolar (I, II, or NOS) disorder, schizoaffective disorder, schizophrenia, or other Axis I psychotic disorder; 3. Meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for current major depressive episode (MDE); 4. HAM-D-17 baseline score = 8 5. Any current Axis I or Axis II diagnoses; 6. A woman who is pregnant or breastfeeding; 7. Meeting DSM-IV criteria for substance dependence in the last 6 months, except for nicotine, or substance abuse in the last 2 months; 8. Positive urine drug screen at evaluation visit; 9. Any current history for an unstable general medical condition (GMC) that requires hospitalization or deemed by investigator to be clinically significant; 10. Any current history for a moderate or severe acute or chronic medical condition that, based on the judgment of the PI or appropriate medical personnel would exclude the subject i.e. epilepsy, unstable hypothyroidism; If a subject is deemed eligible from the above criteria, there is additional exclusion criteria required to participate in Martinos Center study visits. Subjects meeting any of the below criteria will not be allowed to participate in visits to the Martinos Center: 11. Subjects of weight above 300 lbs. (limit for 1.5T Siemens Sonata whole body scanner used in MRI data acquisition); 12. History of significant head trauma (unconsciousness for 10 minutes or longer); 13. Surgical aneurysm clips; 14. Cardiac pacemaker; 15. Prosthetic heart valve; 16. Use of a neurostimulator; 17. Implanted pumps; 18. Cochlear implants; 19. Metal rods, plates, or screws in the body, or metal foil medical skin patches that cannot be removed; 20. IUD; 21. Previous head surgery; 22. Hearing aid; 23. Non-removable dentures, root canals, dental implants, bridges, and wires in the mouth; 24. Currently breastfeeding; 25. Meniere's Disease; 26. Metal (shiny) tattoos or metal body jewelry that cannot be removed; 27. Claustrophobia; 28. Abnormal hearing; 29. Glasses with vision correction greater than +/- 6 diopters. |
Country | Name | City | State |
---|---|---|---|
United States | Depression Clinical and Research Program, MGH | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Wyss Institute at Harvard University | Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Massachusetts Institute of Technology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Biomarkers | Objective biomarkers in voice, physiological, motor and brain imaging signals | Participants will be followed for an expected average of 9 weeks of data collection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |